Thalidomide In Relapsed Or Refractory Patients With Multiple Myeloma: Monotherapy Or Combination Therapy? A Report From Systematic Reviews.

Axel Glasmacher,Corinna Hahn,Florian Hoffmann, Kerstin Furkert,Marie von Lilienfeld-Toal,K. Orlopp,Ralph Naumann,Hartmut Goldschmidt,Ingo G.H. Schmidt-Wolf,Marcus Gorschlueter

BLOOD（2005）

引用 24|浏览12

暂无评分

摘要

The activity of thalidomide monotherapy in relapsed or refractory disease is widely accepted but many haematologists have observed better response rates with combination therapies. This communication aims to give an overview on the efficacy of these alternatives.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要